Krystal Biotech (KRYS) Stock Jumps As Q3 Results Put Buyback First

Krystal Biotech just posted Q3 2026 results with VYJUVEK revenue of US$127.3 million and diluted earnings per share of US$2.05, yet the real story is how that collides with sentiment. The stock came into today under pressure over the last month and quarter, then jumped 3.1% to about US$305 after the release. That move looks tied to one thing that matters most right now: Krystal is throwing its weight behind a US$400 million share repurchase, a bold signal for a profitable rare disease player that already holds roughly US$1.2b in cash and investments.

Love that Krystal Biotech is producing earnings and backing them with a US$400 million buyback but want more profitable rare disease and biotech stocks with strong balance sheets in the mix too? Scan the list of solid balance sheet and fundamentals stocks (24 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): US$127.3 million vs. US$97.8 million (up roughly 30%)
• Net Income (Q3 2026 vs Q3 2025): US$63.1 million vs. US$79.4 million (down about 20%)
• Basic EPS (Q3 2026 vs Q3 2025): US$2.13 vs. US$2.74 (declined roughly 22%)
• Gross Margin (Q3 2026 vs Q3 2025): 94% vs. 96% (slight margin compression)

Tired of scrolling through earnings tables and raw figures for Krystal Biotech? Get a clear visual read on its valuation, financials, balance sheet strength, insider ownership and more in the full company report for Krystal Biotech.

Krystal Biotech: Profit Engine Tested Against Expansion Goals

Krystal Biotech’s bullish script hinges on using VYJUVEK cash flows to build a broader genetic medicines franchise without letting spending run away from revenue.

"The main thing that has to go right is successful execution of global VYJUVEK launches and HSV-1 platform programs in ocular, pulmonary, dermatologic and oncology indications, while keeping operating expenses in check as the company scales."

The latest quarter supports that ambition on two fronts. Commercially, VYJUVEK delivered US$127.3 million of sales with a 94% gross margin and international uptake now contributing meaningfully. On costs, non GAAP R&D and SG&A guidance was tightened down to a range of US$155 to 165 million, and G&A actually declined year on year, showing early discipline while pipeline trials advance.

The price and this Narrative do not agree. → Uncover what this Narrative says Krystal Biotech is actually worth.

Evaluating Krystal Biotech’s Cost Pressure Fears

Bearish investors worry that Krystal Biotech’s rich gross margins may conceal an expense base that could outgrow future franchises.

"While Krystal Biotech reports a high gross margin near 95% and a cash and investments balance above US$1.0b, rising operating expenses tied to global commercialization and pipeline headcount, with G&A already at about US$40 million per quarter, create a path where earnings compress if new products do not scale quickly enough to absorb this higher fixed cost base."

Q3 results challenge that script. Non GAAP R&D and SG&A guidance was cut to US$155 to 165 million for 2026, below the earlier US$175 to 195 million band. G&A actually declined year on year. Net income of US$63.1 million and diluted EPS of US$2.05 still softened versus last year, so margin pressure is present, but management is already curbing expense growth rather than letting it run unchecked.

Hunt For Quiet Mispricings

Krystal Biotech just reminded investors how quickly sentiment can swing around a single quarter. The real opportunity sits in finding stocks that could be undervalued before expectations reset.

• Company 1 - 43% below our estimate - target rising demand for large LED displays as software, services and a streamlined factory footprint reshape operations.
• Company 2 - 29% below our estimate - grow a digital banking platform where higher customer engagement and an improving efficiency ratio shape the business model.
• Company 3 - 39% below our estimate - turn high volume lidar shipments and production ramp contracts into a mix of hardware scale and profitability.

Three companies from the same screener. Open every one of the 34 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com